Paysign/$PAYS
1D1W1MYTD1Y5YMAX
Capital at risk
About Paysign
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.
- Ticker
- $PAYS
- Sector
- Finance
- Primary listing
- NASDAQ
- Employees
- 226
- Headquarters
- Henderson, United States
- Website
- www.paysign.com
Paysign Metrics
BasicAdvanced
$735M
50.28
$0.26
0.76
-
Price and volume
Market cap
$735M
Beta
0.76
52-week high
$14.43
52-week low
$3.08
Average daily volume
806K
Financial strength
Current ratio
1.139
Quick ratio
0.527
Long term debt to equity
8.011
Total debt to equity
9.492
Profitability
EBITDA (TTM)
27.108
Gross margin (TTM)
61.00%
Net profit margin (TTM)
15.67%
Operating margin (TTM)
17.62%
Effective tax rate (TTM)
21.58%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
3.88%
Return on equity (TTM)
30.82%
Valuation
Price to earnings (TTM)
50.282
Price to revenue (TTM)
7.124
Price to book
12.21
Price to tangible book (TTM)
21.08
Price to free cash flow (TTM)
10.611
Free cash flow yield (TTM)
9.42%
Free cash flow per share (TTM)
1.226
Growth
Revenue change (TTM)
46.84%
Earnings per share change (TTM)
116.92%
3-year revenue growth (CAGR)
33.40%
10-year revenue growth (CAGR)
27.66%
3-year earnings per share growth (CAGR)
135.38%
10-year earnings per share growth (CAGR)
17.84%
What the Analysts think about Paysign
Analyst ratings (Buy, Hold, Sell) for Paysign stock.
Analyst projections of the future price of Paysign stock.
Bulls say / Bears say
Paysign reported record Q2 2026 revenue of $28.3 million, up 48.1% year-over-year, driven by broad demand across its plasma and patient affordability segments. (FT)
Pharma segment revenue surged 88.9% year-over-year to $14.65 million in Q2 2026, with 51 net patient affordability programs added over the past 12 months, ending the quarter with 148 active programs and underscoring robust, high-margin growth. (FT)
Paysign raised its full-year 2026 revenue guidance to $106.5 million–$110.5 million, targeting 30%–35% growth and forecasting margin expansion across gross profit, operating income, and adjusted EBITDA. (SEC)
Paysign’s operations exhibit pronounced seasonality, with patient affordability revenues peaking in the first half of the year and plasma revenues typically weakest in Q1, introducing lumpiness that may pressure quarterly consistency. (Reuters)
Paysign’s cost of revenues rose 42.2% year-over-year in Q1 2026, driven by a $901K increase in call center support expenses amid wage inflation, $266K in higher commission expenses, and $1.77M in network fees, indicating ongoing cost pressures that could compress margins. (SEC)
Paysign's shares traded at $9.59 following its Q2 report, near the 52-week high of $9.60, suggesting that valuation may already reflect significant growth and could limit upside from current levels. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Paysign Financial Performance
Revenues and expenses
Paysign Earnings Performance
Company profitability
Upcoming events
No upcoming events
Paysign News
AllArticlesVideos
Funds containing Paysign
Fund name | Fund size | $PAYS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.